Journal of Pathology and Translational Medicine

Cheol-Keun Park

2 Articles

Prognostic Significance of BCL9 Expression in Hepatocellular Carcinoma: Jiyeon Hyeon, Soomin Ahn, Jae Jun Lee, Dae Hyun Song, Cheol-Keun Park; Korean J Pathol. 2013;47(2):130-136. Published online April 24, 2013; DOI: https://doi.org/10.4132/KoreanJPathol.2013.47.2.130

8,395 View
69 Download
18 Crossref

Background

BCL9 enhances β-catenin-mediated transcriptional activity regardless of the mutational status of the Wnt signaling components and increases the cell proliferation, migration, invasion, and metastatic potential of tumor cells. The goal of this study was to elucidate the prognostic significance of BCL9 protein expression in hepatocellular carcinoma (HCC) patients.

Methods

We evaluated BCL9 protein expression by immunohistochemistry in tumor tissue from 288 primary HCC patients who underwent curative hepatectomy. The impact of BCL9 expression on the survival of the patients was analyzed. The median follow-up period was 97.1 months.

Results

Nuclear BCL9 protein expression was observed in 74 (25.7%) of the 288 HCCs. BCL9 expression was significantly associated with younger age (p=0.038), higher Edmondson grade (p=0.001), microvascular invasion (p=0.013), and intrahepatic metastasis (p=0.017). Based on univariate analyses, BCL9 expression showed an unfavorable influence on both disease-free survival (DFS, p=0.012) and disease-specific survival (DSS, p=0.032). Multivariate analyses revealed that higher Barcelona Clinic Liver Cancer stage was an independent predictor of both shorter DFS (p<0.001) and shorter DSS (p<0.001). BCL9 expression tended to be an independent predictor of shorter DFS (p=0.078).

Conclusions

BCL9 protein expression might be a marker of shorter DFS in HCC patients after curative hepatectomy.

Citations

Citations to this article as recorded by

The Wnt-dependent and Wnt-independent functions of BCL9 in development, tumorigenesis, and immunity: Implications in therapeutic opportunities
Minjie Wu, Heng Dong, Chao Xu, Mengqing Sun, Haojin Gao, Fangtian Bu, Jianxiang Chen
Genes & Diseases.2024; 11(2): 701. CrossRef
The role of BCL9 genetic variation as a biomarker for hepatitis C-related hepatocellular carcinoma in Egyptian patients
Eman Abd El Razek Abbas, Ahmed Barakat Barakat, Mohamed Hassany, Samar Samir Youssef
Journal of Genetic Engineering and Biotechnology.2022; 20(1): 4. CrossRef
Molecular Targets and Signaling Pathways of microRNA-122 in Hepatocellular Carcinoma
Kwang-Hoon Chun
Pharmaceutics.2022; 14(7): 1380. CrossRef
Wnt/β-Catenin Signalling and Its Cofactor BCL9L Have an Oncogenic Effect in Bladder Cancer Cells
Roland Kotolloshi, Mieczyslaw Gajda, Marc-Oliver Grimm, Daniel Steinbach
International Journal of Molecular Sciences.2022; 23(10): 5319. CrossRef
Bcl9 Depletion Modulates Endothelial Cell in Tumor Immune Microenvironment in Colorectal Cancer Tumor
Zhuang Wei, Mei Feng, Zhongen Wu, Shuru Shen, Di Zhu
Frontiers in Oncology.2021;[Epub] CrossRef
Wnt Signaling Pathway Is among the Drivers of Liver Metastasis
Ivana Samaržija
Livers.2021; 1(4): 180. CrossRef
Nuclear Expression of Pygo2 Correlates with Poorly Differentiated State Involving c-Myc, PCNA and Bcl9 in Myanmar Hepatocellular Carcinoma
Myo Win Htun, Yasuaki Shibata, Kyaw Soe, Takehiko Koji
ACTA HISTOCHEMICA ET CYTOCHEMICA.2021; 54(6): 195. CrossRef
Wnt status-dependent oncogenic role of BCL9 and BCL9L in hepatocellular carcinoma
Nicole Huge, Maria Sandbothe, Anna K. Schröder, Amelie Stalke, Marlies Eilers, Vera Schäffer, Brigitte Schlegelberger, Thomas Illig, Beate Vajen, Britta Skawran
Hepatology International.2020; 14(3): 373. CrossRef
Structure and function of Pygo in organ development dependent and independent Wnt signalling
Yan Shi, Xiushan Wu, Shuoji Zhu, Huanlei Huang, Jian Zhuang, Haiyun Yuan, Wuzhou Yuan, Ping Zhu
Biochemical Society Transactions.2020; 48(4): 1781. CrossRef
BCL9/BCL9L in hepatocellular carcinoma: will it or Wnt it be the next therapeutic target?
Akshata Moghe, Satdarshan P. Monga
Hepatology International.2020; 14(4): 460. CrossRef
Loss of BCL9/9l suppresses Wnt driven tumourigenesis in models that recapitulate human cancer
David M. Gay, Rachel A. Ridgway, Miryam Müller, Michael C. Hodder, Ann Hedley, William Clark, Joshua D. Leach, Rene Jackstadt, Colin Nixon, David J. Huels, Andrew D. Campbell, Thomas G. Bird, Owen J. Sansom
Nature Communications.2019;[Epub] CrossRef
Immunohistochemical Mapping of Bcl9 Using Two Antibodies that Recognize Different Epitopes Is Useful to Characterize Juvenile Development of Hepatocellular Carcinoma in Myanmar
Myat Thu Soe, Yasuaki Shibata, Myo Win Htun, Kuniko Abe, Kyaw Soe, Nay Win Than, Thann Lwin, Myat Phone Kyaw, Takehiko Koji
ACTA HISTOCHEMICA ET CYTOCHEMICA.2019; 52(1): 9. CrossRef
Low BCL9 expression inhibited ovarian epithelial malignant tumor progression by decreasing proliferation, migration, and increasing apoptosis to cancer cells
Jing Wang, Mingjun Zheng, Liancheng Zhu, Lu Deng, Xiao Li, Linging Gao, Caixia Wang, Huimin Wang, Juanjuan Liu, Bei Lin
Cancer Cell International.2019;[Epub] CrossRef
SOX7 Suppresses Wnt Signaling by Disrupting β-Catenin/BCL9 Interaction
Rong Fan, HaiYan He, Wang Yao, YanFeng Zhu, XunJie Zhou, MingTai Gui, Jing Lu, Hao Xi, ZhongLong Deng, Min Fan
DNA and Cell Biology.2018; 37(2): 126. CrossRef
Hypoxia activates Wnt/β-catenin signaling by regulating the expression of BCL9 in human hepatocellular carcinoma
Wei Xu, Wang Zhou, Mo Cheng, Jing Wang, Zhian Liu, Shaohui He, Xiangji Luo, Wending Huang, Tianrui Chen, Wangjun Yan, Jianru Xiao
Scientific Reports.2017;[Epub] CrossRef
Hepatocellular carcinoma biology predicts survival outcome after liver transplantation in the USA
Mohamed Abd El-Fattah
Indian Journal of Gastroenterology.2017; 36(2): 117. CrossRef
miR-30a acts as a tumor suppressor by double-targeting COX-2 and BCL9 in H. pylori gastric cancer models
Xuan Liu, Qing Ji, Chengcheng Zhang, Xiaowei Liu, Yanna Liu, Ningning Liu, Hua Sui, Lihong Zhou, Songpo Wang, Qi Li
Scientific Reports.2017;[Epub] CrossRef
BCL9, a coactivator for Wnt/β-catenin transcription, is targeted by miR-30c and is associated with prostate cancer progression
XIAO-HUI LING, ZHI-YUN CHEN, HONG-WEI LUO, ZE-ZHEN LIU, YING-KE LIANG, GUAN-XING CHEN, FU-NENG JIANG, WEI-DE ZHONG
Oncology Letters.2016; 11(3): 2001. CrossRef

CHD1L Is a Marker for Poor Prognosis of Hepatocellular Carcinoma after Surgical Resection: Jiyeon Hyeon, Soomin Ahn, Cheol-Keun Park; Korean J Pathol. 2013;47(1):9-15. Published online February 25, 2013; DOI: https://doi.org/10.4132/KoreanJPathol.2013.47.1.9

8,180 View
70 Download
22 Crossref

Abstract PDF

Background

The gene for chromodomain helicase/ATPase DNA binding protein 1-like (CHD1L) was recently identified as a target oncogene within the 1q21 amplicon, which occurs in 46% to 86% of primary hepatocellular carcinoma (HCC) cases. However, the prognostic significance of CHD1L in HCC remains uncertain. In this study, we investigated the roles of CHD1L in the prognosis of HCC.

Methods

We investigated the expressions of CHD1L in tumor tissue microarrays of 281 primary HCC patients who underwent surgical resection using immunohistochemistry. Prognostic factors of HCC were examined by univariate and multivariate analyses. The median follow-up period was 75.6 months.

Results

CHD1L expression was observed in 48 of the 281 HCCs (17.1%). CHD1L expression was associated with a younger age (p=0.033), higher Edmondson grade (p=0.019), microvascular invasion (p<0.001), major portal vein invasion (p=0.037), higher American Joint Committee on Cancer T stage (p=0.001), lower albumin level (p=0.047), and higher α-fetoprotein level (p=0.002). Multivariate analyses revealed that CHD1L expression (p=0.027), Edmondson grade III (p=0.034), and higher Barcelona Clinic Liver Cancer stage (p<0.001) were independent predictors of shorter disease-free survival.

Conclusions

CHD1L expression might be a prognostic marker of shorter disease-free survival in HCC patients after surgical resection.

Citations

Citations to this article as recorded by

Targeted Inhibition of CHD1L by OTI-611 Reprograms Chemotherapy and Targeted Therapy-Induced Cell Cycle Arrest and Suppresses Proliferation to Produce Synergistic Antitumor Effects in Breast and Colorectal Cancer
Hector Esquer, Qiong Zhou, Daniel V. LaBarbera
Cells.2025; 14(5): 318. CrossRef
The validation of new CHD1L inhibitors as a therapeutic strategy for cancer
Sophia Clune, Paul Awolade, Qiong Zhou, Hector Esquer, Brock Matter, Jeffrey T. Kearns, Timothy Kellett, Damilola Caleb Akintayo, Uday B. Kompella, Daniel V. LaBarbera
Biomedicine & Pharmacotherapy.2024; 170: 116037. CrossRef
Role of pelitinib in the regulation of migration and invasion of hepatocellular carcinoma cells via inhibition of Twist1
Sewoong Lee, Eunjeong Kang, Unju Lee, Sayeon Cho
BMC Cancer.2023;[Epub] CrossRef
Design, Synthesis, and Biological Evaluation of the First Inhibitors of Oncogenic CHD1L
Brett J. Prigaro, Hector Esquer, Qiong Zhou, Laura A. Pike, Paul Awolade, Xin-He Lai, Adedoyin D. Abraham, Joshua M. Abbott, Brock Matter, Uday B. Kompella, Wells A. Messersmith, Daniel L. Gustafson, Daniel V. LaBarbera
Journal of Medicinal Chemistry.2022; 65(5): 3943. CrossRef
Diversity roles of CHD1L in normal cell function and tumorigenesis
Xifeng Xiong, Xudong Lai, Aiguo Li, Zhihe Liu, Ningfang Ma
Biomarker Research.2021;[Epub] CrossRef
Elevated serum alpha-fetoprotein levels are associated with poor prognosis of hepatocellular carcinoma after surgical resection: A systematic review and meta-analysis
Hong-Lin Chen, Yu-Hua Chen, Lin Du, Yi-Ping Song, Bin Zhu
Arab Journal of Gastroenterology.2021; 22(1): 12. CrossRef
Genome-wide scanning for CHD1L gene in papillary thyroid carcinoma complicated with type 2 diabetes mellitus
Y. Y. Kang, J. J. Li, J. X. Sun, J. X. Wei, C. Ding, C. L. Shi, G. Wu, K. Li, Y. F. Ma, Y. Sun, H. Qiao
Clinical and Translational Oncology.2021; 23(12): 2536. CrossRef
The high expression of CHD1L and its clinical significance in human solid tumors
Long Zhang, Yufen Jiang, Panpan Jiao, Xiaohong Deng, Yuancai Xie
Medicine.2021; 100(10): e24851. CrossRef
Clinical Significance of Trk Receptor Expression as a New Therapeutic Target in Hepatocellular Carcinoma
Sangjoon Choi, Sujin Park, Yoon Ah Cho, Cheol-Keun Park, Sang Yun Ha
Pathology & Oncology Research.2020; 26(4): 2587. CrossRef
Hepatocyte ploidy and pathological mutations in hepatocellular carcinoma: impact on oncogenesis and therapeutics
Taiji Yamazoe, Taizo Mori, Sachiyo Yoshio, Tatsuya Kanto
Global Health & Medicine.2020; 2(5): 273. CrossRef
First-in-Class Inhibitors of Oncogenic CHD1L with Preclinical Activity against Colorectal Cancer
Joshua M. Abbott, Qiong Zhou, Hector Esquer, Laura Pike, Travis P. Broneske, Sébastien Rinaldetti, Adedoyin D. Abraham, Dominique A. Ramirez, Paul J. Lunghofer, Todd M. Pitts, Daniel P. Regan, Aik Choon Tan, Daniel L. Gustafson, Wells A. Messersmith, Dani
Molecular Cancer Therapeutics.2020; 19(8): 1598. CrossRef
Prognostic role of chromodomain helicase DNA binding protein 1-like protein in human solid cancers
Wanwei Liu, Jiwei Xu, Caiyun Zhang
Medicine.2018; 97(29): e11522. CrossRef
CHD1L Expression Increases Tumor Progression and Acts as a Predictive Biomarker for Poor Prognosis in Pancreatic Cancer
Chuan Liu, Xiaowei Fu, Zhiwei Zhong, Jing Zhang, Haiyan Mou, Qiong Wu, Tianle Sheng, Bo Huang, Yeqing Zou
Digestive Diseases and Sciences.2017; 62(9): 2376. CrossRef
Overexpression of CHD1L is associated with poor survival and aggressive tumor biology in esophageal carcinoma
Ze-Han Liu, Qi Zhang, Yi-Jie Ding, Ying-Hui Ren, Hui-Peng Yang, Qing Xi, Ying-Nan Cheng, Guo-Lin Miao, Hong-Kun Liu, Cai-Xia Li, Wen-Qiang Yan, Yan Li, Zhenyi Xue, Lijuan Zhang, Xin-Ye Li, Chen-Long Zhao, Yurong Da, Xian-Zhong Wu, Jun-Qiang Chen, Rongxin
Oncotarget.2017; 8(43): 74178. CrossRef
CHD1L Regulates Cell Cycle, Apoptosis, and Migration in Glioma
Jie Sun, Li Zhang, Hongyu Zhao, Xiaojun Qiu, Wenjuan Chen, Donglin Wang, Na Ban, Shaochen Fan, Chaoyan Shen, Xiaojie Xia, Bin Ji, Yuchan Wang
Cellular and Molecular Neurobiology.2016; 36(4): 565. CrossRef
Expression of DBC1 is associated with poor prognosis in hepatitis virus-related hepatocellular carcinoma
Sang Yun Ha, Jeong Hoon Kim, Jung Wook Yang, Hyunsik Bae, Hae Yon Cho, Cheol-Keun Park
Pathology - Research and Practice.2016; 212(7): 616. CrossRef
The Overexpression of CCAR1 in Hepatocellular Carcinoma Associates with Poor Prognosis
Sang Yun Ha, Jeong Hoon Kim, Jung Wook Yang, Jimin Kim, Binnari Kim, Cheol-Keun Park
Cancer Research and Treatment.2016; 48(3): 1065. CrossRef
Genetic alterations in hepatocellular carcinoma: An update
Zhao-Shan Niu, Xiao-Jun Niu, Wen-Hong Wang
World Journal of Gastroenterology.2016; 22(41): 9069. CrossRef
CHD1L is a novel independent prognostic factor for gastric cancer
Z. Su, J. Zhao, G. Xian, W. Geng, Z. Rong, Y. Wu, C. Qin
Clinical and Translational Oncology.2014; 16(8): 702. CrossRef
Presence of CHD1L Over-Expression Is Associated with Aggressive Tumor Biology and Is a Novel Prognostic Biomarker for Patient Survival in Human Breast Cancer
Jiayi Wu, Yu Zong, Xiaochun Fei, Xiaosong Chen, Ou Huang, Jianrong He, Weiguo Chen, Yafen Li, Kunwei Shen, Li Zhu, Xin-Yuan Guan
PLoS ONE.2014; 9(8): e98673. CrossRef
CHD1L: a novel oncogene
Wen Cheng, Yun Su, Feng Xu
Molecular Cancer.2013; 12(1): 170. CrossRef
Expression of CHD1L in bladder cancer and its influence on prognosis and survival
Feng Tian, Feng Xu, Zheng-Yu Zhang, Jing-Ping Ge, Zhi-Feng Wei, Xiao-Feng Xu, Wen Cheng
Tumor Biology.2013; 34(6): 3687. CrossRef

Author index